How to Select the Right CD16a (FcγRIIIa) Variant for FcγR Binding StudiesPUBLISHED
How to Select the Right CD16a (FcγRIIIa) Variant for FcγR Binding Studies
TL;DR
CD16a comes in two common allotypes — V158 (high affinity) and F158 (low affinity) — and they are *not* interchangeable. Choose based on what your study is trying to model: V158 to mimic high-responder donors / screen for potency, F158 to represent the lower-affinity majority. And never use an Fc-fusion CD16a for kinetics without accounting for avidity.
1. Biology in one paragraph
CD16a (FcγRIIIa) is the activating Fc receptor on NK cells and macrophages that drives ADCC. A single nucleotide polymorphism (rs396991, V/F at position 158) changes its affinity for IgG1: the 158V allotype binds IgG1 more tightly (~2–5× higher affinity reported in the literature) and V/V donors show stronger ADCC responses. This polymorphism is why "CD16a" is not one protein — it's two functionally distinct reagents.
2. Which variant when?
| Study goal | Recommended variant | Reason |
|---|---|---|
| Screen for ADCC-potent mAbs | V158 | Higher affinity amplifies differences between candidates |
| Model average-donor response | F158 | Majority of the population carries at least one F allele |
| Fc engineering (afucosylation, mutations) | Both, side by side | Best practice — improvements should hold on both allotypes |
| Clinical-response correlation | Match your donor cohort genotype | Don't infer donor genetics from a single allotype |
3. Assay design
- SPR/BLI capture: biotinylated CD16a (ECD, validated allotype) on streptavidin → flow monomeric IgG1 (e.g., rituximab, trastuzumab) → K<sub>D</sub>.
- Reference data: your supplier should provide K<sub>D</sub> against a named reference antibody (not "a control IgG") so you can benchmark lot-to-lot.
- Allotype proof: the COA must state the allele (V158/F158) *and* how it was verified (sequencing or mass spec). Don't trust the catalog number alone.
4. Common mistakes
- Avidity from Fc-fusion CD16a — Fc-fused receptors dimerize; reported "nM" affinities are often avidity-inflated. Use monomeric ECD (His or biotinylated) for true kinetics.
- Glycosylation blind spots — HEK293 vs CHO glycosylation changes FcγR binding; state the expression system and keep it consistent across studies.
- Ignoring the allotype — comparing experiments run on V158 vs F158 without noting it; always record the allele in your methods.
- ADCC assay ≠ binding assay — SPR affinity does not equal killing; use cell-based ADCC for functional claims.
5. What to request from your supplier
- COA stating variant (V158/F158) with verification method
- SPR K<sub>D</sub> vs a named reference IgG1 (e.g., trastuzumab)
- Expression system + glycosylation notes
- Biotinylated version (for capture-based assays)
6. Related resources
- [CD16a Proteins — V158 & F158, biotinylated](/hero/cd16a)
- [ADCC Evaluation & SPR/BLI Service](/services/spr-bli)
- [Custom CD16a Constructs](/services/custom-protein)
What next?
- [Buy CD16a (V158 or F158)](/request?utm_campaign=cd16a-variant-guide&utm_source=site&utm_medium=organic&utm_content=cta-buy) — allotype-verified, SPR data vs reference antibody
- [Request a Sample](/request?utm_campaign=cd16a-variant-guide&utm_source=site&utm_medium=organic&utm_content=cta-sample) — compare both allotypes side by side
- [Discuss Your Experiment](/request?utm_campaign=cd16a-variant-guide&utm_source=site&utm_medium=organic&utm_content=cta-discuss) — we'll help you pick the variant and format for your readout
Next steps